elbasvirbased
Elbasvir is a medication used in combination with grazoprevir for the treatment of chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) that works by inhibiting the HCV NS5A protein, which is essential for viral replication. Elbasvir is typically prescribed as part of a combination therapy, often with other DAAs, to achieve a high cure rate.
The combination of elbasvir and grazoprevir is known as Epclusa, a fixed-dose tablet that simplifies treatment
Elbasvir is administered orally and is generally well-tolerated, with common side effects including headache, fatigue, and
Elbasvir is a significant advancement in the treatment of hepatitis C, offering a more convenient and effective